Oxbryta® (voxelotor) – Expanded indication, new formulation approval
On December 17, 2021, Global Blood Therapeutics announced the FDA approval of Oxbryta (voxelotor), for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older.
Download PDF
